Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, PanCancer Atlas 2018)

Overview

TCGA PanCancer Atlas 2018 dataset for cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC). Used as a reference/comparison cohort in genomic landscape studies of cervical cancer. PMID:37643132

Composition

  • TCGA multi-platform genomic profiling of cervical squamous cell carcinoma and endocervical adenocarcinoma. PMID:37643132
  • Used as a comparison dataset against MSK cohort (cervix_msk_2023) for mutation frequency analysis. PMID:37643132
  • KRAS mutation frequency in TCGA was 5%, significantly lower than the MSK cohort (12%, P=0.019). PMID:37643132

Assays / panels (linked)

  • Multi-platform TCGA profiling: whole-exome sequencing, RNA-seq, copy-number arrays. PMID:37643132

Papers using this cohort

  • PMID:37643132 — Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets.

Notable findings derived from this cohort

  • Served as a reference for mutation frequency comparisons in CESC; KRAS mutations were 5% in TCGA vs. 12% in the MSK cohort, highlighting potential enrichment in a clinical cancer center population. PMID:37643132
  • MC3 ensemble mutation calls (7 callers, 10,510 TCGA tumor/normal pairs, 33 cancer types) form the somatic-variant backbone of this PanCanAtlas cBioPortal study PMID:29596782
  • Pan-cancer aneuploidy analysis of 10,522 TCGA tumors placed this cohort in the squamous cluster (3p loss, 3q gain) alongside LUSC, ESCC, and HPV-negative HNSC PMID:29622463

Sources

This page was processed by entity-page-writer on 2026-05-15.